Full Press Release Details
Adaptive Phase II Study of BAN2401 in Early Alzheimer’s Disease Continues toward 18-Month Endpoint.
BIIB
Adaptive Phase II Study of BAN2401 in Early Alzheimer’s Disease Continues toward 18-Month Endpoint
Key Takeaway: Adaptive Phase II Study of BAN2401 in Early Alzheimer’s Disease Continues toward 18-Month Endpoint
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis